Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis

Benjamin Z Leder, Bruce Mitlak, Ming-Yi Hu, Gary Hattersley, Richard S Bockman, Benjamin Z Leder, Bruce Mitlak, Ming-Yi Hu, Gary Hattersley, Richard S Bockman

Abstract

Context: The ACTIVE study demonstrated the antifracture efficacy of abaloparatide in postmenopausal women with osteoporosis. ACTIVExtend demonstrated sustained fracture risk reduction with alendronate in abaloparatide-treated participants from ACTIVE. A direct comparison of the efficacy of abaloparatide and antiresorptive therapies has not been performed.

Objective: The objective of this analysis is to compare the antifracture efficacy of abaloparatide in ACTIVE with that of alendronate in ACTIVExtend.

Design: In this post hoc analysis, the rate of new vertebral fractures for women in ACTIVExtend (N = 1139) was calculated based on baseline and endpoint radiographs for placebo or abaloparatide in ACTIVE and alendronate in ACTIVExtend. Vertebral fracture rates between abaloparatide and alendronate were compared in a Poisson regression model. Fracture rates for nonvertebral and clinical fractures were compared based on a Poisson model during 18 months of abaloparatide or placebo treatment in ACTIVE and 18 months of alendronate treatment in ACTIVExtend.

Results: The vertebral fracture rate was lower during abaloparatide treatment in ACTIVE (0.47 fractures/100 patient-years) than alendronate treatment in ACTIVExtend (1.66 fractures/100 patient-years) (relative risk reduction 71%; P = .027). Although the comparisons did not meet statistical significance, after switching from placebo (ACTIVE) to alendronate (ACTIVExtend), the rate of new vertebral fractures decreased from 2.49 to 1.66 fractures per 100 patient-years, and after switching from abaloparatide to alendronate from 0.47 to 0.19 fractures per 100 patient-years. The rates of nonvertebral fractures and clinical fractures were not significantly different.

Conclusion: Initial treatment with abaloparatide may result in greater vertebral fracture reduction compared with alendronate in postmenopausal women with osteoporosis.

Trial registration: ClinicalTrials.gov NCT01343004 NCT01657162.

Keywords: abaloparatide; alendronate; nonvertebral fractures; osteoporosis; vertebral fractures.

© Endocrine Society 2019.

Figures

Figure 1.
Figure 1.
Study design for ACTIVE and ACTIVExtend. Women were randomly assigned 1:1:1 to double-blind abaloparatide (80 μg/d), matching placebo, or open-label teriparatide (20 μg/d) for 18 months. Women from the abaloparatide and placebo groups were eligible to enter the 24-month extension, during which they were treated with alendronate (70 mg/d). Stars indicate the treatment groups being compared in this analysis. ABL, abaloparatide; ACTIVE, Abaloparatide Comparator Trial In Vertebral Endpoints; ALN, alendronate; PBO, placebo; SC, subcutaneously; TPTD, teriparatide. From Bone HG, Cosman F, Miller PD, et al. ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab. 2018;103(8):2949–2957 (11) under the CC-BY license.
Figure 2.
Figure 2.
Comparison of new vertebral fracture event rate between alendronate- and abaloparatide-treated participants (ACTIVExtend mITT population), showing the reduction of new vertebral fractures in the placebo/alendronate (gray bar) and abaloparatide (green bar) groups from ACTIVE and in participants from each of these groups treated with alendronate (purple bars) during ACTIVExtend. ABL, abaloparatide; ACTIVE, Abaloparatide Comparator Trial In Vertebral Endpoints; ALN, alendronate; mITT, modified intent-to-treat; PBO, placebo.

References

    1. Office of the Surgeon General (US). Bone Health and Osteoporosis: A Report of the Surgeon General. . 2004. Accessed June 6, 2019.
    1. Camacho PM, Petak SM, Binkley N, et al. . American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2016. Endocr Pract. 2016;22(Suppl 4):1–42.
    1. Singer A, Exuzides A, Spangler L, et al. . Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. Mayo Clin Proc. 2015;90(1):53–62.
    1. Lems WF, Raterman HG. Critical issues and current challenges in osteoporosis and fracture prevention. An overview of unmet needs. Ther Adv Musculoskelet Dis. 2017;9(12):299–316.
    1. Watts NB, Bilezikian JP, Camacho PM, et al. ; AACE Osteoporosis Task Force American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2010;16(Suppl 3):1–37.
    1. Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 2017;5(11):898–907.
    1. Pavone V, Testa G, Giardina SMC, Vescio A, Restivo DA, Sessa G. Pharmacological therapy of osteoporosis: a systematic current review of literature. Front Pharmacol. 2017;8:803.
    1. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007;357(9):905–916.
    1. Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ. Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology. 2016;157(1):141–149.
    1. Miller PD, Hattersley G, Riis BJ, et al. ; ACTIVE Study Investigators Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316(7):722–733.
    1. Bone HG, Cosman F, Miller PD, et al. . ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab. 2018;103(8):2949–2957.
    1. Kendler DL, Marin F, Zerbini CAF, et al. . Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391(10117):230–240.
    1. Saag KG, Petersen J, Brandi ML, et al. . Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417–1427.
    1. Cosman F, Miller PD, Williams GC, et al. . Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial. Mayo Clin Proc. 2017;92(2):200–210.
    1. Bliuc D, Nguyen TV, Eisman JA, Center JR. The impact of nonhip nonvertebral fractures in elderly women and men. J Clin Endocrinol Metab. 2014;99(2):415–423.
    1. Roux C, Wyman A, Hooven FH, et al. ; GLOW investigators Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW). Osteoporos Int. 2012;23(12):2863–2871.
    1. Black DM, Cummings SR, Karpf DB, et al. . Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348(9041):1535–1541.
    1. Cummings SR, Black DM, Thompson DE, et al. . Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280(24):2077–2082.
    1. Dempster DW, Zhou H, Recker RR, et al. . Differential effects of teriparatide and denosumab on intact PTH and bone formation indices: AVA osteoporosis study. J Clin Endocrinol Metab. 2016;101(4):1353–1363.
    1. McClung MR, San Martin J, Miller PD, et al. . Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 2005;165(15):1762–1768.
    1. Tsai JN, Uihlein AV, Lee H, et al. . Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 2013;382(9886):50–56.
    1. Hadji P, Zanchetta JR, Russo L, et al. . The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int. 2012;23(8):2141–2150.
    1. Saag KG, Shane E, Boonen S, et al. . Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357(20):2028–2039.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever